Association of immunological parameters with aortic dilatation in giant cell arteritis: a cross-sectional study

[1]  M. Brodmann,et al.  Prevalence and prognostic factors for aortic dilatation in giant cell arteritis - a longitudinal study. , 2020, Seminars in arthritis and rheumatism.

[2]  C. Crowson,et al.  Incidence and predictors of thoracic aortic damage in biopsy-proven giant cell arteritis , 2020, Scandinavian journal of rheumatology.

[3]  Jian Zhang,et al.  Serum amyloid a protein as a potential biomarker in predicting acute onset and association with in-hospital death in acute aortic dissection , 2019, BMC Cardiovascular Disorders.

[4]  H. Okamura,et al.  Deletion of interleukin-18 attenuates abdominal aortic aneurysm formation. , 2019, Atherosclerosis.

[5]  P. Merkel,et al.  Evaluation of Potential Serum Biomarkers of Disease Activity in Diverse Forms of Vasculitis , 2019, The Journal of Rheumatology.

[6]  Tao Zeng,et al.  Cytokines in aortic dissection. , 2018, Clinica chimica acta; international journal of clinical chemistry.

[7]  A. Aouba,et al.  Mortality causes and trends associated with giant cell arteritis: analysis of the French national death certificate database (1980–2011) , 2018, Rheumatology.

[8]  G. Thallinger,et al.  A concise review of significantly modified serological biomarkers in giant cell arteritis, as detected by different methods. , 2017, Autoimmunity reviews.

[9]  G. Wei,et al.  Serum High-Sensitive C-Reactive Protein Level and CRP Genetic Polymorphisms Are Associated with Abdominal Aortic Aneurysm. , 2017, Annals of vascular surgery.

[10]  E. Matteson,et al.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities , 2017, Nature Reviews Rheumatology.

[11]  E. Matteson,et al.  The spectrum of giant cell arteritis and polymyalgia rheumatica: revisiting the concept of the disease , 2016, Rheumatology.

[12]  M. Tomšič,et al.  Do Early Diagnosis and Glucocorticoid Treatment Decrease the Risk of Permanent Visual Loss and Early Relapses in Giant Cell Arteritis , 2016, Medicine.

[13]  G. Ailawadi,et al.  Interleukin-6 Receptor Inhibition Prevents Descending Thoracic Aortic Aneurysm Formation. , 2015, The Annals of thoracic surgery.

[14]  D. Veale,et al.  Regulation of Inflammation and Angiogenesis in Giant Cell Arteritis by Acute‐Phase Serum Amyloid A , 2015, Arthritis & rheumatology.

[15]  A. Boots,et al.  Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica. , 2015, Rheumatology.

[16]  P. Stather,et al.  Meta‐analysis and meta‐regression analysis of biomarkers for abdominal aortic aneurysm , 2014, The British journal of surgery.

[17]  Xian-liang Zhou,et al.  Value of D-dimer and C reactive protein in predicting inhospital death in acute aortic dissection , 2013, Heart.

[18]  Matthias F Kriegel,et al.  Distribution, determinants, and normal reference values of thoracic and abdominal aortic diameters by computed tomography (from the Framingham Heart Study). , 2013, The American journal of cardiology.

[19]  A. Morgan,et al.  Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis , 2012, Annals of the rheumatic diseases.

[20]  S. Gabriel,et al.  Large-vessel involvement in giant cell arteritis: a population-based cohort study of the incidence-trends and prognosis , 2012, Annals of the rheumatic diseases.

[21]  M. Eagleton,et al.  Interleukin-5 is a potential mediator of angiotensin II-induced aneurysm formation in apolipoprotein E knockout mice. , 2012, The Journal of surgical research.

[22]  D. Klatzmann,et al.  Interleukin-21 modulates Th1 and Th17 responses in giant cell arteritis. , 2012, Arthritis and rheumatism.

[23]  F. Ohsuzu,et al.  Deficiency of interleukin-1 receptor antagonist promotes spontaneous femoral artery aneurysm formation in mice. , 2012, The American journal of pathology.

[24]  Mahboob Rahman,et al.  Tissue and serum markers of inflammation during the follow-up of patients with giant-cell arteritis—a prospective longitudinal study , 2011, Rheumatology.

[25]  Thomas S Riles,et al.  Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. , 2010, Journal of vascular surgery.

[26]  D A Bloch,et al.  The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. , 2010, Arthritis and rheumatism.

[27]  R. Olshen,et al.  Th17 and Th1 T-Cell Responses in Giant Cell Arteritis , 2010, Circulation.

[28]  Gregory J. Hardy,et al.  Interferon- (cid:1) and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm Formation and Rupture Molecular Cardiology , 2009 .

[29]  C. Nicolau,et al.  Development of aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: a cross-sectional screening of fifty-four prospectively followed patients. , 2008, Arthritis and rheumatism.

[30]  Arik Wolak,et al.  Aortic size assessment by noncontrast cardiac computed tomography: normal limits by age, gender, and body surface area. , 2008, JACC. Cardiovascular imaging.

[31]  Brenda S. Cho,et al.  Attenuation of Experimental Aortic Aneurysm Formation in P‐Selectin Knockout Mice , 2006, Annals of the New York Academy of Sciences.

[32]  V. Lesauskaitė,et al.  Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology. , 2006, Human pathology.

[33]  T. Wakefield,et al.  L-Selectin–Mediated Neutrophil Recruitment in Experimental Rodent Aneurysm Formation , 2005, Circulation.

[34]  G. Fraedrich,et al.  High Prevalence of Circulating CD4+CD28− T-Cells in Patients With Small Abdominal Aortic Aneurysms , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[35]  G. Hunder,et al.  Aortic Aneurysm and Dissection in Patients With Biopsy-Proven Giant Cell Arteritis From Northwestern Spain: A Population-Based Study , 2004, Medicine.

[36]  G. Hunder,et al.  Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: a population-based study over 50 years. , 2003, Arthritis and rheumatism.

[37]  G. Hoffman,et al.  Large-vessel vasculitis: unresolved issues. , 2003, Arthritis and rheumatism.

[38]  J. Fernandez-Solà,et al.  A strong initial systemic inflammatory response is associated with higher corticosteroid requirements and longer duration of therapy in patients with giant-cell arteritis. , 2002, Arthritis and rheumatism.

[39]  Josep Maria Salanova Grau,et al.  Circulating soluble adhesion molecules in patients with giant cell arteritis. Correlation between soluble intercellular adhesion molecule-1 (sICAM-1) concentrations and disease activity , 1999, Annals of the rheumatic diseases.

[40]  B. Baslund,et al.  Mortality in patients with giant cell arteritis. , 2015, Rheumatology.

[41]  N. Arden,et al.  The relative risk of aortic aneurysm in patients with giant cell arteritis compared with the general population of the UK. , 2015, Annals of the rheumatic diseases.

[42]  V. Aboyans,et al.  [2014 ESC Guidelines on the diagnosis and treatment of aortic diseases]. , 2014, Kardiologia polska.